---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000055"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-04-04T23:59:59+00:00"
generated_at: "2026-06-17T06:29:00.737487+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences gets FDA Fast Track for CB-011 CAR-T in relapsed/refractory multiple myeloma

## Summary
- CB-011 is an allogeneic anti-BCMA CAR-T with immune cloaking (B2M-HLA-E transgene).
- Fast Track designation enables expedited FDA review and more frequent agency interactions.
- CaMMouflage Phase 1 trial enrolling at dose level 1; first patient dosed recently.
- CB-011 aims to be an off-the-shelf option avoiding apheresis and long manufacturing times.

## SEC filing metadata
- accession: 0001619856-23-000055
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-04-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000055/0001619856-23-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000055/crbu-20230404.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000055
- JSON: https://secwatch.observer/filing/0001619856-23-000055.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.